Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Total Non-Current Liabilities (2016 - 2025)

Fate Therapeutics (FATE) has disclosed Total Non-Current Liabilities for 14 consecutive years, with $109.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Non-Current Liabilities fell 9.72% year-over-year to $109.6 million, compared with a TTM value of $109.6 million through Dec 2025, down 9.72%, and an annual FY2025 reading of $109.6 million, down 9.72% over the prior year.
  • Total Non-Current Liabilities was $109.6 million for Q4 2025 at Fate Therapeutics, roughly flat from $109.2 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $262.8 million in Q2 2021 and bottomed at $105.2 million in Q1 2025.
  • Average Total Non-Current Liabilities over 5 years is $169.8 million, with a median of $143.1 million recorded in 2023.
  • The sharpest move saw Total Non-Current Liabilities skyrocketed 150.36% in 2021, then plummeted 39.14% in 2023.
  • Year by year, Total Non-Current Liabilities stood at $218.4 million in 2021, then decreased by 0.31% to $217.8 million in 2022, then tumbled by 36.72% to $137.8 million in 2023, then decreased by 11.87% to $121.4 million in 2024, then dropped by 9.72% to $109.6 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for FATE at $109.6 million in Q4 2025, $109.2 million in Q3 2025, and $109.9 million in Q2 2025.